Cross Country Healthcare, Inc. CCRN R2K
Company Overview
Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance; vendor neutral and managed services programs; and education healthcare, caregiver services, and outsourcing services. This segment offers staffing solutions for registered nurses, licensed practical nurses, certified nurse assistants, practitioners, pharmacists, and other allied professionals on per diem and short-term assignments; and clinical and non-clinical professionals on long-term assignments, as well as workforce solutions, including MSP, VMS, RPO, project management, and other outsourcing and consultative services. It also provides retained search services for healthcare professionals, as well as contingent search and recruitment process outsourcing services. The company serves public and private acute care and non-acute care hospitals, government facilities, local and national healthcare plans, managed care providers, public and charter schools, outpatient clinics, ambulatory care facilities, correctional facilities, PACE programs, physician practice groups, and other healthcare providers. The Physician Staffing segment provides physicians in various specialties, certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments. This segment serves various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. The company was founded in 1986 and is headquartered in Boca Raton, Florida.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.05B (-21.6% YoY); net profit $-94.85M.
- Trailing 12 Months Year-on-year growth — revenue -17.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.64% |
| 1 Year: | -17.80% |
Stock Price Performance
| 1 Year: | +9.60% |
| 6 Months: | +57.43% |
| 3 Months: | +35.52% |
| 1 Month: | +0.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)74.30 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CCRN Cross Country Healthcare, Inc. R2K | 13.24 | -4.34 | $427.74M | 0.00% | -22.74% | -26.98% | 2.64% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 210.29M | 204.57M | 200.72M | 200.91M | 195.17M | 202.76M | 209.20M | 215.10M | 210.06M | 216.78M | 193.97M | 215.61M | 329.24M | 331.83M | 374.90M | 640.68M | 788.73M | 753.56M | 636.10M | 628.22M | 622.71M | 540.70M | 442.29M | 414.04M | 379.17M | 339.77M | 315.12M | 309.94M | 293.41M | 274.07M | 250.05M | 236.76M | 241.06M |
| Gross Profit | 54.85M | 58.21M | 57.63M | 53.27M | 56.53M | 60.48M | 58.30M | 53.75M | 53.69M | 51.56M | 50.56M | 48.25M | 51.59M | 51.01M | 53.16M | 49.60M | 50.73M | 48.00M | 54.39M | 71.47M | 72.59M | 83.79M | 147.15M | 174.79M | 170.41M | 143.54M | 138.94M | 139.42M | 123.14M | 97.36M | 90.49M | 77.30M | 70.81M | 64.16M | 61.99M | 58.66M | 56.00M | 50.93M | 47.98M | - |
| Operating Income | -17.02M | 9.33M | - | 3.25M | 6.45M | 8.37M | - | 4.25M | 4.34M | 2.65M | - | -2.69M | -15.10M | 119.00K | - | -754.00K | -13.69M | -381.00K | - | 20.99M | 15.90M | 26.45M | - | 90.63M | 78.84M | 52.17M | - | 43.80M | 35.19M | 20.30M | - | 2.92M | -19.21M | 2.85M | - | -977.00K | -5.86M | -5.97M | - | -4.16M |
| Net Income | -17.24M | 14.07M | -7.88M | -2.01M | 4.85M | 6.72M | 27.95M | 1.64M | 1.54M | -441.00K | -19.69M | -1.77M | -51.67M | -3.13M | -1.14M | -2.09M | -14.15M | -1.33M | 4.61M | 19.45M | 11.55M | 23.43M | 77.57M | 61.98M | 52.89M | 34.79M | 38.79M | 29.44M | 21.34M | 12.81M | 9.04M | 2.69M | -16.05M | 2.56M | -3.75M | -490.00K | -6.66M | -4.77M | -82.93M | -4.27M |
| Diluted EPS | -0.54 | 0.22 | -0.24 | -0.08 | 0.13 | 0.19 | 0.77 | 0.05 | 0.04 | -0.01 | -0.55 | -0.05 | -1.44 | -0.09 | -0.03 | -0.06 | -0.39 | -0.04 | 0.13 | 0.53 | 0.31 | 0.62 | 2.07 | 1.63 | 1.40 | 0.93 | 1.05 | 0.81 | 0.60 | 0.36 | 0.26 | 0.08 | -0.47 | 0.08 | -0.12 | -0.02 | -0.20 | -0.15 | -2.56 | -0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 833.54M | 865.05M | 816.48M | 822.22M | 836.42M | 1.68B | 2.80B | 2.02B | 1.34B | 1.05B |
| Operating Income | 17.70M | -3.81M | 5.91M | -24.52M | -8.02M | -10.47M | 20.57M | 6.18M | 11.75M | -12.88M | -15.71M | -9.16M | 139.30M | 269.88M | 112.71M | -16.86M | -84.41M |
| Net Income | 6.69M | -2.77M | 4.10M | -42.22M | -51.97M | -31.78M | 4.42M | 7.97M | 37.51M | -16.95M | -57.71M | -12.96M | 132.00M | 185.98M | 72.63M | -14.56M | -94.85M |
| Diluted EPS | 0.22 | -0.09 | 0.13 | -1.37 | -1.68 | -1.02 | 0.14 | 0.15 | 1.01 | -0.48 | -1.61 | -0.36 | 3.53 | 4.95 | 2.05 | -0.44 | -2.93 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 343.66M | 347.94M | 305.92M | 248.25M | 325.13M | 365.60M | 388.38M | 467.69M | 427.00M | 382.37M | 356.97M | 732.81M | 949.59M | 681.06M | 589.25M | 448.95M |
| Total Equity | 234.02M | 246.07M | 246.01M | 249.30M | 209.12M | 160.67M | 129.88M | 140.85M | 151.24M | 237.09M | 217.53M | 162.63M | 154.38M | 294.26M | 451.48M | 467.65M | 418.96M | 322.82M |
| Cash & Equivalents | 10.17M | 6.86M | 10.96M | 10.65M | 10.46M | 8.05M | 5.00M | 2.45M | 20.63M | 25.54M | 16.02M | - | 1.60M | 1.04M | 3.60M | 17.09M | 81.63M | 108.74M |
| Long Term Debt | - | - | - | - | - | - | - | - | 84.75M | 92.26M | 77.94M | 70.97M | 55.83M | 181.76M | 150.68M | - | - | - |
| Total Liabilities | - | - | 97.65M | 98.64M | 96.80M | 87.58M | 194.80M | 224.25M | 236.58M | 229.97M | 208.81M | 218.87M | 202.06M | 435.28M | 498.11M | 213.41M | 170.29M | 126.13M |
| Current Liabilities | - | - | 35.25M | 51.09M | 72.59M | 44.91M | 67.00M | 86.05M | 97.09M | 94.59M | 85.39M | 85.47M | 93.42M | 199.77M | 279.13M | 156.08M | 120.40M | 77.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 31.52M | 18.30M | 10.15M | 8.66M | -4.07M | 18.23M | 30.14M | 45.51M | 21.00M | 5.54M | 27.20M | -85.62M | 134.05M | 248.50M | 120.12M | 48.25M |
| Investing Cash Flow | - | -16.20M | -4.20M | 175.00K | 15.21M | -45.45M | -24.07M | -9.78M | -91.38M | -6.68M | -2.94M | -4.62M | -34.05M | -43.87M | -13.78M | -8.71M | -8.16M |
| Financing Cash Flow | - | -11.19M | -14.24M | -10.58M | -26.06M | 46.46M | 3.35M | -2.16M | 50.76M | -23.77M | -17.60M | -22.01M | 119.09M | -87.60M | -221.24M | -46.85M | -13.01M |
| Capital Expenditure | -2.45M | -2.39M | -4.00M | -2.22M | -1.75M | -4.57M | -2.36M | -6.52M | -5.11M | -4.60M | -2.94M | -4.62M | -7.17M | -8.79M | -13.97M | -8.71M | -8.16M |
| Free Cash Flow | - | 29.13M | 14.30M | 7.93M | 6.91M | -8.64M | 15.87M | 23.62M | 40.40M | 16.40M | 2.60M | 22.59M | -92.79M | 125.26M | 234.52M | 111.40M | 40.09M |
| Share Buybacks | - | - | 2.23M | 374.00K | 0 | 0 | - | 0 | 0 | 5.00M | 0 | 0 | 0 | 35.28M | 57.65M | 37.31M | 6.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | 0.7% | 1.4% | -1.6% | -1.9% | -1.1% | 8.3% | 9.6% | 5.6% | -1.3% | -8.0% |
| Net Margin % | - | - | - | - | - | - | - | 1.0% | 4.3% | -2.1% | -7.0% | -1.5% | 7.9% | 6.6% | 3.6% | -1.1% | -9.0% |
| ROE % | 2.7% | -1.1% | 1.6% | -20.2% | -32.3% | -24.5% | 3.1% | 5.3% | 15.8% | -7.8% | -35.5% | -8.4% | 44.9% | 41.2% | 15.5% | -3.5% | -29.4% |
| ROCE % | - | -1.2% | 2.0% | -10.5% | -3.9% | -4.1% | 7.4% | 2.1% | 3.1% | -3.8% | -5.3% | -3.5% | 26.1% | 40.3% | 21.5% | -3.6% | -22.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Boston Partners | 7.88% | 2.55M | $33.65M |
| 2 | Blackrock Inc. | 7.76% | 2.51M | $33.14M |
| 3 | Dimensional Fund Advisors LP | 4.98% | 1.61M | $21.28M |
| 4 | Vanguard Capital Management LLC | 4.24% | 1.37M | $18.11M |
| 5 | Sio Capital Management, LLC | 3.40% | 1.10M | $14.52M |
| 6 | Quinn Opportunity Partners, LLC | 3.17% | 1.03M | $13.56M |
| 7 | Charles Schwab Investment Management, Inc. | 2.95% | 952.12K | $12.59M |
| 8 | American Century Companies Inc | 2.93% | 948.13K | $12.53M |
| 9 | Oddo BHF Asset Management SAS | 2.91% | 940.00K | $12.43M |
| 10 | Dana Investment Advisors, Inc. | 2.89% | 933.22K | $12.34M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CCRN
CCRN Stock Alert: Halper Sadeh LLC is Investigating Whether Cross Country Healthcare, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxPRXEtMDUxNTVEaWJ2V3o1ZzNBNmZ4REhaTkJ5UE9iXzV5OTV1OEUtWHZvNjRwQ1BNQU5weTdJdkVzb3MtSWxhekhrWUFTZm10bjNFYnVhR2xUZllMa3ZEUGlodkJlUkVXLW9zbGRPb3k1Vk5YdGs2ck5aR3Vka25FWGJKNXM2Um8xYnVJMz…
Cross Country Healthcare (NASDAQ: CCRN) CAO logs tax-related share withholding in Form 4 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPM2NFazNNUV91b081T0FHT2txZjk2TUx0dnNQVDdnTkdQeVFuaXFMa3d0OVFMSEFyb2Q1YWY0R0dmWEJ1czA0TDNhM3B3Ump3VmQ2a2lmMnVWa2hlREJlWTJmNUNrNDFMV0dwc3FYbVZZeU5ldDdzemt5bWJVYWdyVDYxTV9GR2ozZzM0X3…
Behavioral Patterns of CCRN and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxObkh3ZjEyZm9temc5UWpZMFBNdEtYczMzSW4taEpPQk40aXBXVGtGZnkxSXJyVzVjNnhYUko2eUUxUHRLQm9PX1o2N1ozMERLd2tXUXN5R3pkS0w4bHVkRzFVOWZ6TFg3dG80QXVDalJ5VG4wRjc0UHhnX3l6V1VjT0NiQXlpa0c5YVBIYT…
How The Cross Country Healthcare (CCRN) Story Is Shifting With Margin Goals And Travel Nurse Demand - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNaTBEMXZUSE9IX0ZCcnJac3dGU1VfU01Dc00tVTY2ZDZ0UWMycWN0SmNLVmwtVmN5Y2RXbWJndXJFelR2aXNLMjVDQWh4MXNLcmcwNnFZYm84UlY5R1BxbnpUMTkxTGl5Y3NzUFVFa1BrUXBmZkN0U01RZDgybmhwWTJtV2daT0VKZzFNMC…
Cross Country Healthcare, Inc. Actuals & Estimates (NASDAQ:CCRN) - TradingView
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOMjEzY0NCaVRNbzhpcHhZTTRwSEd3cjJZNElmLXFTdGFJVFl0c1FtdUhveTVzTktKNFpJNDB3YkVNd0xvZHJvQllWTWcxZUtnNU5xQzZBaTc4aVNYc1NCT0pQWjZUVWhjX2VVX2hncVozNVg4Si15d2xKdGU0U09WYWdzUnFIdw?oc=5" t…
Cross Country Healthcare Inc. (CCRN) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbUpBQm9YeFR5bjlNYWY4YmFiWGNaTk1yOVlqWUdhWk51RE96ZTd0dWFfc3BfTUwzc0hPOGpQdkNlbG5CNk5oMkh1NWhMaEhxSkc0ZzU5bUdkNTRrS3A3UW1hbjR0M0ZsMmpCc204LUg5SUNhTHNHOGNYVjF6MGxmSUJsODV2eUpSYklxcz…
CCRN — Frequently Asked Questions
What is the current share price of Cross Country Healthcare, Inc. (CCRN)?
As of 2026-07-15 16:51 PDT, Cross Country Healthcare, Inc. (CCRN) trades at $13.24 on NasdaqGS. Its 52-week range is $7.53 to $14.23.
What is the market capitalisation of CCRN?
Cross Country Healthcare, Inc. (CCRN) has a market capitalisation of $427.74M on NasdaqGS.
What is the P/E ratio of CCRN?
CCRN trades at a trailing price-to-earnings (P/E) ratio of -4.34. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.32.
What is the return on equity (ROE) of CCRN?
CCRN has a return on equity (ROE) of -26.98%. Its return on capital employed (ROCE) is -22.74%.
Is CCRN a good stock to buy?
This page provides a data-driven analysis of Cross Country Healthcare, Inc. (CCRN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.